Although only 1% of GBM tumours exhibit RAS mutation or amplification, 10% of GBM tumours contain inactivating genetic alterations of neurofibromin 1 (NF1) that lead to hyperactive RAS activity by enhancing intrinsic GTPase activity [62, 70]. The gene discussed is NF1; the disease is neoplasm.